Skip to main content

Table 4 Modulation of cytotoxicity by zosuquidar and the P-gp activity in 31 patient cells

From: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

   RMF Uptake
  Resistance Modifiding DNR/Ida MITOX Mylotarg DIOC2 +Zosu
P01 No 1.1 0.6 1.0 0.06
P02 Yes/DNR, Ida, Mylotarg 2.3/3.2 20% 35%e 0.53
P03 No 0.7 ND 0.8 0.05
P04 No 0.8 ND 1.3 0.1
P05 No 1.1 0.92 1.1 0.05
P06 Yes/Mylotarg ND ND 4.1 0.7
P07 Yes/Mylotarg 1.6 ND 29% 0.46
P08 No 1.0 ND 1.2 0.13
P09 No 0.7/1.2 ND 1.0 0.24
P10 No 1.0/1.0 ND 1.0 0.33
P11 No 0.9 ND 13% 0.4
P12 Yes/MITOX ND 2.1 ND 0.6
P13 No 0.9 1.1 0.9 0.13
P14 No 1.1 ND ND 0.23
P15 No 1.1 1.3 1.0 0.13
P16 Yes/DNR, Mitox 6.6 2.1 ND 0.04
P17 No 1.0 1.0 0.9 0.05
P18 No 1.1 0.9 1.0 0.06
P19 No 1.0 1.0 1.0 0
P20 Yes/DNR, Mylotarg 1.4 ND 3 0.38
P21 No ND ND 0.5 0.12
P22 No 1.2 1 1 0.21
P23 No 1.1 1.0 1.0 0.21
P24 No ND ND 1.1 0.06
P25 Yes/DNR, Mitox, Mylo 2.5 2.3 30% 0.05
P26 No 1 ND ND 0.04
P27 No 0.87 0.82 ND 0.24
P28 No 0.7 1.2 ND 0
P29 Yes/Mylotarg ND ND 2.0 0.04
P30 No 1.0 1.1 1.0 0.08
P31 No 1.2 ND 9% 0.26
  1. a. RMF: ratio of IC50 in the presence of zosuquidar over the IC50 in the absence of zosuquidar.
  2. b. The concentration of DNR, Ida and Mitox was varied from 5 to 1000 nM.
  3. c. The concentration of Mylotarg was varied from 12.5 to 1000 ng/ml.
  4. d. ND: Non determiner due to missing the cells, or IC50 was out of the concentration measured.
  5. e. Results on percentage when IC50 could not be able to determine, and X% cell death more in presence of zosuquidar than without zosuquidar.